Arizona Isotope Science Research Funding, Investors & Competitors

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Mammoth Biosciences is a biotechnology company, co-founded by CRISPR pioneer Jennifer Doudna, that develops CRISPR-based tools for diagnostics and gene-editing therapeutics. Its platform is built around compact Cas proteins such as Cas14 and Casφ, which the company applies to in vivo gene editing for genetic and infectious diseases as well as decentralized disease detection. Mammoth has partnered with organizations including Regeneron, GSK, and the NIH, and has received government funding to develop COVID-19 testing technology.

Embark is a Boston-based canine genetics company offering DNA testing kits. The platform analyzes over 200,000 genetic markers using CLIA-certified SNP chips to screen for breed, health risks, traits, and preventive care recommendations, contributing to veterinary research on nutrition and diseases.

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

ArsenalBio is a South San Francisco-based, clinical-stage cell therapy company that engineers CAR T-cell therapies using CRISPR-based genome editing and logic-gating technology. Its pipeline targets solid tumors including ovarian, kidney, and prostate cancers, with its lead candidate, AB-2100, in Phase 1/2 trials for clear-cell renal cell carcinoma under a collaboration with Bristol-Myers Squibb. The platform is designed to address T-cell exhaustion, tumor specificity, and genome toxicity, challenges that have limited CAR T therapies in solid tumors.

BGI Group is a Shenzhen-headquartered global leader in genomics, operating as Shenzhen Huada Gene Technology Co. Ltd. The company delivers DNA sequencing, bioinformatics testing, genetic analysis, agricultural genomics, and proteomics services. With operations centered in China and international labs, it contributed to the Human Genome Project and advances precision medicine worldwide.

Sangon Biotech is a Shanghai-based biotechnology firm specializing in nucleic acid synthesis and molecular biology products. Founded in 2003 as a Sino-foreign joint venture, it manufactures DNA/RNA oligonucleotides, gene synthesis services, peptides, enzymes, reagents, lab consumables, and benchtop instruments. The company operates a production base in Songjiang Industrial Park, serving research institutions and pharmaceutical companies worldwide.

Everlywell is an Austin, Texas-based digital health company, founded in 2015, that sells at-home lab testing kits for conditions including cholesterol, thyroid health, fertility, testosterone, food sensitivities, and sexually transmitted infections, with results reviewed by physicians through partnered labs. The company added COVID-19 sample collection kits in March 2020, scaling to handle up to 250,000 tests per week during the pandemic. Its direct-to-consumer model combines e-commerce sales of test kits with lab fees, physician review, and subscription revenue for repeat testing.

Element Biosciences is a San Diego-based life sciences company building next-generation DNA sequencing instruments. The AVITI platform delivers high-accuracy reads using avidity sequencing chemistry, reducing costs through improved signal-to-noise ratios in surface chemistry and biochemistry. Launched in 2022, it supports workflows from short-read to long-read applications for genomics research. Element Biosciences serves academic labs, biopharma, and clinical sequencing markets worldwide.

Immunai is a biotechnology company with locations in New York City, San Francisco, and Tel Aviv, mapping the immune system using single-cell genomics and machine learning. The firm profiles hundreds of immune cell types from blood samples via its proprietary database, aiding biomarker discovery for therapeutics in autoimmune diseases and cancer.

Delfi Diagnostics is a Baltimore-headquartered developer of blood-based cancer screening tests using AI and genome sequencing. Its Delfi test analyzes DNA fragmentation patterns to detect lung cancer at 89 percent sensitivity in stage I cases. Clinical trials with Johns Hopkins involve over 1,000 patients, targeting multi-cancer early detection. Founded in 2019 by genome experts, the company secured FDA breakthrough designation in 2023.

Demant is a Denmark-based manufacturer and distributor of hearing solutions, such as hearing aid devices and diagnostic equipment. More than 80% of the company's sales come from North America and Europe.

Wilson Wolf Corporation is a medical device manufacturer headquartered in Eden Prairie, Minnesota, producing gas-permeable cell culture flasks and bioreactors for mammalian cell expansion in applications like monoclonal antibody production, stem cell therapy, and tissue engineering. Established in 1998, the company supplies platforms used by researchers at Mayo Clinic and universities for immunotherapy and diabetes research.

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.